Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT).
نویسندگان
چکیده
منابع مشابه
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.
BACKGROUND Excess cardiovascular mortality has been documented in chronic haemodialysis patients. Oxidative stress is greater in haemodialysis patients with prevalent cardiovascular disease than in those without, suggesting a role for oxidative stress in excess cardiovascular disease in haemodialysis. We investigated the effect of high-dose vitamin E supplementation on cardiovascular disease ou...
متن کاملReappraisal of role of angiotensin receptor blockers in cardiovascular protection
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have shown cardioprotective and renoprotective properties. These agents are recommended as first-line therapy for the treatment of hypertension and the reduction of cardiovascular risk. Early studies pointed to the cardioprotective and renoprotective effects of ARBs in high-risk patients. The ONgoing Telmi...
متن کاملCardiovascular and Renal Effects of Hibiscus Sabdariffa Linnaeus. in Patients with Diabetic Nephropathy: A Randomized, Double-Blind, Controlled Trial
Background: Hibiscus sabdariffa linnaeus (HSL) is a tropical plant with a high content of anthocyanin, traditionally found to have beneficial biological activities. This randomized, double-blind, placebo-controlled, and parallel trial was conducted to assess some renal and cardiovascular effects of supplementation with HSL in patients with diabetic nephropathy. Methods: The study protocol was c...
متن کاملRenal transplantation in diabetic nephropathy.
Forty diabetics who had developed end-stage renal failure from diabetic nephropathy and underwent renal transplantation have been followed up from one to six years. After one and two years 63% and 42% survived (45% and 33% respectively with functioning kidneys). Older patients, those with coronary and peripheral vascular disease, and those with severe neuropathy are prone to higher postoperativ...
متن کاملGenomic Damage in Endstage Renal Disease—Contribution of Uremic Toxins
Patients with end-stage renal disease (ESRD), whether on conservative, peritoneal or hemodialysis therapy, have elevated genomic damage in peripheral blood lymphocytes and an increased cancer incidence, especially of the kidney. The damage is possibly due to accumulation of uremic toxins like advanced glycation endproducts or homocysteine. However, other endogenous substances with genotoxic pro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nihon Naika Gakkai Zasshi
سال: 2011
ISSN: 0021-5384,1883-2083
DOI: 10.2169/naika.100.3386